|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury:A review显示文摘Matrix metalloproteinases(MMPs) are a family ofproteases using zinc-dependent catalysis to break down extracellular matrix(ECM) components, allowing cell movement and tissue reorganization. Like many other proteases, MMPs are produced as zymogens, an inactive form, which are activated after their release from cells. Hepatic ischemia/reperfusion(I/R) is associated with MMP activation and release, with profound effects on tissue integrity: their inappropriate, prolonged or excessive expression has harmful consequences for the liver. Kupffer cells and hepatic stellate cells can secrete MMPs though sinusoidal endothelial cells are a further source of MMPs. After liver transplantation, biliary complications are mainly attributable to cholangiocytes, which, compared with hepatocytes, are particularly susceptible to injury and ultimately a major cause of increased graft dysfunction and patient morbidity. This paper focuses on liver I/R injury and cholestasis and reviews factors and mechanisms involved in MMP activation together with synthetic compounds used in their regulation. In this respect, recent data have demonstrated that the role of MMPs during I/R may go beyond the mere destruction of the ECM and may be much more complex than previously thought. We thus discuss the role of MMPs as an important factor in cholestasis associated with I/R injury. | Giuseppina Palladini Andrea Ferrigno Plinio Richelmi Stefano Perlini Mariapia Vairetti | 2015 | World Journal of Gastroenterology2015，21，42： | 6 |
| 2 | Lobe-Specific Heterogeneity and Matrix Metalloproteinase Activation after Ischemia/Reperfusion Injury in Rat Livers显示文摘 | Giuseppina Palladini Andrea Ferrigno Vittoria Rizzo Eleonora Boncompagni Plinio Richelmi Isabel Freitas Stefano Perlini Mariapia Vairetti | 2012 | Toxicologic Pathology2012，，5： | 2 |
| 3 | Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan,dexamethasone,and thalidomide显示文摘 | Palladini G Russo P Lavatelli F | 2009 | Ann Hematol2009，88，2： | 1 |
| 4 | New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes 显示文摘 | Palladini G Dispenzieri A Gertz MA | 2012 | J Clin Oncol2012，30，36： | 1 |
| 5 | Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation显示文摘 | Palladini G Perfetti V Obici L | 2004 | Blood2004，103，8： | 1 |
| 6 | Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine显示文摘 | Palladini G Russo P Bosoni T | | 0，，03： | 1 |
| 7 | Amyloidosis is a cure possible显示文摘 | Merlini G Palladini G | 2008 | Ann On-col2008，19，14： | 1 |
| 8 | Clinical aspects of systemic amyloid diseases显示文摘 | Obici L Perfetti V Palladini G | 2005 | Biochim Biophys Acta2005，1753，： | 1 |
| 9 | Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure 显示文摘 | Palladini G Foli A Milani P et 81 | 2012 | Am J Hematol2012，87，5： | 1 |
| 10 | Lung matrix metallo- proteiuase activation following partial hepatic ischemia/reperfusion injury in rats 显示文摘 | Palladini G Ferrigno A Rizzo V | 2014 | Scientific World Journal2014，，： | 1 |
| 11 | The recovery of ant communities in regenerating tem- perate conifer forests 显示文摘 | PALLADINI J D JONES M G SANDERS N J | 2007 | Forest Ecology and Manage- ment2007，242，2： | 1 |
| 12 | A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 显示文摘 | Palladini G Sachchithanantham S Milani P | 2015 | Blood2015，126，5： | 1 |
| 13 | Light chain amyloidosis 2012: a new era 显示文摘 | Gatt ME Palladini G | 2013 | Sr J Haemato12013，160，5： | 1 |
| 14 | Circulating amyloido- genic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL显示文摘 | Palladini G Lavatelli F Russo P | 2006 | Blood2006，107，10： | 1 |
| 15 | Circulating amyloidogenic free light chains and serum N terminal natriuretic peptide type B decrease simuhaneously in association with improvement of survival in AL显示文摘 | Palladini G Lavatelli F Russo P el al | 2006 | Blood2006，107，10： | 1 |
| 16 | Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis显示文摘 | Palladini G Campana C Klersy C | 2003 | Circulation2003，107，： | 1 |
| 17 | Current treatment of AL amyloidosis 显示文摘 | Palladini G Merlini G | 2009 | Haematological2009，94，8： | 1 |
| 18 | Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 显示文摘 | Palladini G Milani E Foli A | 2014 | Haematologica2014，99，4： | 1 |
| 19 | A reduced complexity estimation algorithm for ultrasound images de-blurring显示文摘 | PALLADINI A TESTONI N | 2009 | Computer Methods and Programs in Biomedicine2009，95，2： | 1 |
| 20 | Current treatment of AL amyloidosis显示文摘 | Palladini G Merlini G | 2009 | Haematological2009，94，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员